Western Financial Corp CA Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Western Financial Corp CA decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 870 shares of the biopharmaceutical company’s stock after selling 833 shares during the quarter. Western Financial Corp CA’s holdings in Regeneron Pharmaceuticals were worth $620,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mizuho Securities USA LLC grew its position in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares during the last quarter. Principal Financial Group Inc. increased its stake in Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares during the period. Simplify Asset Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares in the last quarter. Catalytic Wealth RIA LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $1,334,000. Finally, Daiwa Securities Group Inc. grew its stake in Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock worth $21,428,000 after acquiring an additional 2,234 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research analyst reports. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Evercore ISI dropped their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $672.98 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $73.95 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10. The stock’s 50-day simple moving average is $720.81 and its 200-day simple moving average is $924.07.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.